CY1111636T1 - Εμβολιο που περιεχει gp120 και nef kai/´h tat για ανοσοποιηση εναντι hiv - Google Patents

Εμβολιο που περιεχει gp120 και nef kai/´h tat για ανοσοποιηση εναντι hiv

Info

Publication number
CY1111636T1
CY1111636T1 CY20111100626T CY111100626T CY1111636T1 CY 1111636 T1 CY1111636 T1 CY 1111636T1 CY 20111100626 T CY20111100626 T CY 20111100626T CY 111100626 T CY111100626 T CY 111100626T CY 1111636 T1 CY1111636 T1 CY 1111636T1
Authority
CY
Cyprus
Prior art keywords
polynucleotide
hiv
nef
tat
protein
Prior art date
Application number
CY20111100626T
Other languages
English (en)
Inventor
Peter Franz Ertl
John Philip Tite
Wely Catherine Ann Van
Gerald Voss
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1111636T1 publication Critical patent/CY1111636T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Χρήση α) μια HIV Tat πρωτεΐνης ή πολυνουκλεοτιδίου ή β) μιας HIV Nef πρωτεΐνης ή πολυνουκλεοτιδίου ή γ) μιας HIV Tat πρωτεΐνης ή πολυνουκλεοτιδίου συνδεδεμένων σε μια HIV Nef πρωτεΐνη ή πολυνουκλεοτίδιο και μιας HIV gp 120 πρωτεΐνης ή πολυνουκλεοτιδίου για την παρασκευή ενός εμβολίου κατάλληλου για χορήγηση πρώτης-αναμνηστικής ανοσοποίησης για την προληπτική ή θεραπευτική ανοσοποίηση ανθρώπων έναντι του HIV, όπου η πρωτεΐνη ή το πολυνουκλεοτίδιο χορηγείται μέσω προσέγγισης βομβαρδισμού.
CY20111100626T 2001-07-27 2011-06-29 Εμβολιο που περιεχει gp120 και nef kai/´h tat για ανοσοποιηση εναντι hiv CY1111636T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0118367.2A GB0118367D0 (en) 2001-07-27 2001-07-27 Novel use
EP02791473A EP1411979B1 (en) 2001-07-27 2002-07-26 Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv

Publications (1)

Publication Number Publication Date
CY1111636T1 true CY1111636T1 (el) 2015-10-07

Family

ID=9919328

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100626T CY1111636T1 (el) 2001-07-27 2011-06-29 Εμβολιο που περιεχει gp120 και nef kai/´h tat για ανοσοποιηση εναντι hiv

Country Status (12)

Country Link
US (2) US20050058657A1 (el)
EP (1) EP1411979B1 (el)
JP (2) JP2005507377A (el)
AT (1) ATE504313T1 (el)
CA (1) CA2455329A1 (el)
CY (1) CY1111636T1 (el)
DE (1) DE60239682D1 (el)
DK (1) DK1411979T3 (el)
ES (1) ES2363079T3 (el)
GB (1) GB0118367D0 (el)
PT (1) PT1411979E (el)
WO (1) WO2003011334A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8337861B2 (en) * 2003-01-09 2012-12-25 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
WO2004092195A2 (en) 2003-04-09 2004-10-28 Administrators Of The Tulane Educational Fund Dendritic cell binding proteins and uses thereof
AU2004279991B2 (en) * 2003-10-10 2010-11-25 Powderject Vaccines, Inc. Nucleic acid constructs
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
CA2577183C (en) 2004-08-17 2014-02-18 Institut Gustave Roussy Mutated hiv nef for modulating immunity
GB0507997D0 (en) * 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs
ES2281252B1 (es) * 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
EP1954309A2 (en) * 2005-10-17 2008-08-13 Novartis AG Multiclade hiv vaccines
US8673551B2 (en) 2005-12-07 2014-03-18 Speedx Pty Ltd. Methods, plasmid vectors and primers for assessing HIV viral fitness
AU2008223951B2 (en) * 2007-03-02 2014-03-27 Glaxosmithkline Biologicals S.A. Novel method and compositions
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
GB0802224D0 (en) * 2008-02-06 2008-03-12 Inst Superiore Di Sanito Process for the production of vaccine components
AU2009270771B2 (en) * 2008-07-16 2012-08-23 Baylor Research Institute HIV vaccine based on targeting maximized Gag and Nef to dendritic cells
KR20140045341A (ko) * 2011-02-23 2014-04-16 유니버시티 오브 마이애미 Siv/hiv로부터의 보호를 위한 조합된 세포 기반의 gp96-ig-siv/hiv, 재조합 gp120 단백질 백신접종
JP6934857B2 (ja) 2016-03-14 2021-09-15 三菱瓦斯化学株式会社 オキシメチレン共重合体の製造方法
GB2592769B (en) 2020-03-01 2022-05-04 Valneva Austria Gmbh CpG-Adjuvanted SARS-CoV-2 virus vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2001004280A2 (de) * 1999-07-08 2001-01-18 Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
JP2003529559A (ja) * 2000-01-31 2003-10-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規用途

Also Published As

Publication number Publication date
DE60239682D1 (de) 2011-05-19
US20050058657A1 (en) 2005-03-17
GB0118367D0 (en) 2001-09-19
WO2003011334A1 (en) 2003-02-13
ES2363079T3 (es) 2011-07-20
EP1411979A1 (en) 2004-04-28
JP2010187681A (ja) 2010-09-02
JP2005507377A (ja) 2005-03-17
ATE504313T1 (de) 2011-04-15
CA2455329A1 (en) 2003-02-13
EP1411979B1 (en) 2011-04-06
DK1411979T3 (da) 2011-07-11
PT1411979E (pt) 2011-07-01
US20080102085A1 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
CY1111636T1 (el) Εμβολιο που περιεχει gp120 και nef kai/´h tat για ανοσοποιηση εναντι hiv
AP2002002592A0 (en) Vaccine for the prophylactic or therapeutic immunization against HIV.
CY1118521T1 (el) Συνθεση εμβολιου και μεθοδος χρησης αυτου
AU2001295673A1 (en) Vaccine composition
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
SE0100901D0 (sv) New composition
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
NO991078D0 (no) HIV peptider, antigener, vaksine sammensetninger, immunoassay kit og en metode for Õ pÕvise antistoffer indusert av HIV
AU8499901A (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
WO2005097179A3 (fr) Antigene tat stabilise et ses applications pour la vaccination anti-vih.
EP0317622A4 (en) PREVENTION AND TREATMENT OF RETROVIRUS DISEASE.
WO2002070004A3 (en) Papillomavirus vaccines
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
HUP0303423A2 (hu) HIV elleni természetes ellenanyag
WO2005027835A3 (en) Therapeutic immunization of hiv-infected individuals
WO2003011329A3 (de) Impfstoff für veterinäre und humanmedizinische prophylaxe und therapie von dermatophytosen
WO2004066954A3 (en) A therapeutic composition for the treatment of hiv-1 and hiv-2
AU2002355653A1 (en) Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv
AU2390101A (en) Toscana virus nucleoprotein